Jacob Gunvalson is a 17-year-old boy with a terminal genetic disease called Duchenne muscular dystrophy, but he was not allowed to participate in a drug company’s trial of an experimental drug that holds some promise as a possible cure.
Nicolas Fuca is a 13-year-old boy with the same disease, and he, too, was not allowed into the same company’s experimental trials because he cannot walk — a key standard for participation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
